Supernus Pharma (SUPN) Posts Q2 Revenue Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Supernus Announces Second Quarter 2022 Financial Results
August 4, 2022 4:01 PM EDTSecond quarter 2022 total revenues of $170.1 million, a 20% increase compared to second quarter 2021Second quarter 2022 GAAP operating earnings of $11.3 million; second quarter 2022 non-GAAP operating earnings of $37.6 millionQelbree® continued its growth trajectory, with 62,938 prescriptions in second quarter 2022, a 33% increase compared to first quarter 2022Second quarter 2022 Qelbree net product sales of $11.1 million increased 34% compared to first quarter of 2022; First six months 2022 Qelbree net product sales were $19.4 millionQelbree launched in the U.S. for adult ADHD in May... More
